Skip to content

Avanos Medical AVNS Change in derivative financial instruments

Change in derivative financial instruments at other companies

Ashland logo
AshlandASH
$0-100%
Griffon logo
GriffonGFF
-$773K+29.3%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$200K-74.0%
BankUnited logo
BankUnitedBKU
$272K-97.1%
EVERTEC logo
EVERTECEVTC
$2.75M+169%
Scansource logo
ScansourceSCSC
-$4K+99.1%

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B+108%
Enterprise value$1.24B+105%
P/S1.6×+0.8×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent.

The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's change in derivative financial instruments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's change in derivative financial instruments?
Avanos Medical (AVNS) reported change in derivative financial instruments of $1.5M in Q1 2026.
How has Avanos Medical's change in derivative financial instruments changed year-over-year?
Avanos Medical's change in derivative financial instruments increased by 1600.0% year-over-year, from -$100K to $1.5M.
What does change in derivative financial instruments mean?
Represents the effective portion of gains or losses on derivative instruments designated as cash flow hedges. This metric tracks the company's success in mitigating risks associated with interest rate, commodity, or currency fluctuations.